The ¡°Leuven¡± paclitaxel/carboplatin weekly regimen in patients with recurrent ovarian cancer, a retrospective study

详细信息    查看全文

• 作者：Isabelle Cadron ; ^{Isabelle.Cadron@uz.kuleuven.ac.be} ; Leyla Abdulkadir ; Evelyn Despierre ; Patrick Berteloot ; Patrick Neven ; Karin Leunen ; Fré ; dé ; ric Amant ; Ignace Vergote
• 关键词：Epithelial ovarian cancer ; Weekly administration ; Paclitaxel ; Carboplatin ; Dose dense ; Chemotherapy
• 刊名：Gynecologic Oncology
• 出版年：2013
• 出版时间：January, 2013
• 年：2013
• 卷：128
• 期：1
• 页码：34-37
• 全文大小：196 K

文摘

Objective

To evaluate the ¡°Leuven¡± weekly paclitaxel/carboplatinum (TC) regimen in recurrent ovarian cancer in a retrospective study.

Methods

Eighteen courses of paclitaxel (60 mg/m²) and carboplatinum (AUC 2.7) were administered weekly. Platinum-resistance was defined as progression during or within 6 months after platinum-based chemotherapy.

Results

Sixty-three patients were included with a median number of prior treatment regimens of 4 (range 0-10). Forty-three patients were platinum resistant and 20 were platinum sensitive (14 intermediate sensitive and 5 sensitive). One patient in the platinum resistant group and 2 patients in the platinum sensitive group achieved complete remission, 15 patients in the platinum resistant and 5 patients in the platinum sensitive group achieved partial remission according to RECIST. In the entire patient population evaluable for response (n = 62), the median progression free survival (PFS) was 6.7 months; the median overall survival (OS) was 9.7 months. Median PFS was 6 months for the platinum resistant and 8 months for the platinum sensitive group. The median OS was 9 months in the platinum resistant and 11 months in the platinum sensitive group.

Toxicity was mostly bone marrow related with neutropenia grade 3/4 in 67 % and neutropenic fever in 6 % of patients. Dose reduction was necessary in 24 % of patients. Nausea, vomiting and fatigue were the most frequent non-hematological side effects.

Conclusion

Weekly paclitaxel and carboplatin is an effective regimen for patients with recurrence of ovarian cancer with a response rate of 37 % in platinum resistant disease and a manageable toxicity profile.